ASH 2009 meeting report - Top 10 clinically oriented abstracts in acute leukemia

Amber Fullmer, Jorge Cortes, Hagop Kantarjian, Elias Jabbour

Research output: Contribution to journalArticle

Abstract

The 2009 American Society of Hematology (ASH) annual meeting introduced novel strategies for the treatment of acute leukemia. Targeted inhibitors for both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) represent the future of these malignancies. Inclusion of targeted treatment to combination chemotherapy may translate into improved cure rates. The most clinically relevant abstracts, all of which are published in the November 2009, 114 issue of Blood, are summarized below and are identified here by their abstract numbers.

Original languageEnglish (US)
Pages (from-to)277-280
Number of pages4
JournalAmerican Journal of Hematology
Volume85
Issue number4
DOIs
StatePublished - Apr 1 2010
Externally publishedYes

Fingerprint

Hematology
Leukemia
Combination Drug Therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

ASH 2009 meeting report - Top 10 clinically oriented abstracts in acute leukemia. / Fullmer, Amber; Cortes, Jorge; Kantarjian, Hagop; Jabbour, Elias.

In: American Journal of Hematology, Vol. 85, No. 4, 01.04.2010, p. 277-280.

Research output: Contribution to journalArticle

Fullmer, Amber ; Cortes, Jorge ; Kantarjian, Hagop ; Jabbour, Elias. / ASH 2009 meeting report - Top 10 clinically oriented abstracts in acute leukemia. In: American Journal of Hematology. 2010 ; Vol. 85, No. 4. pp. 277-280.
@article{9a00d64e2cb34d23af5d2f3a64a0b8c9,
title = "ASH 2009 meeting report - Top 10 clinically oriented abstracts in acute leukemia",
abstract = "The 2009 American Society of Hematology (ASH) annual meeting introduced novel strategies for the treatment of acute leukemia. Targeted inhibitors for both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) represent the future of these malignancies. Inclusion of targeted treatment to combination chemotherapy may translate into improved cure rates. The most clinically relevant abstracts, all of which are published in the November 2009, 114 issue of Blood, are summarized below and are identified here by their abstract numbers.",
author = "Amber Fullmer and Jorge Cortes and Hagop Kantarjian and Elias Jabbour",
year = "2010",
month = "4",
day = "1",
doi = "10.1002/ajh.21644",
language = "English (US)",
volume = "85",
pages = "277--280",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - ASH 2009 meeting report - Top 10 clinically oriented abstracts in acute leukemia

AU - Fullmer, Amber

AU - Cortes, Jorge

AU - Kantarjian, Hagop

AU - Jabbour, Elias

PY - 2010/4/1

Y1 - 2010/4/1

N2 - The 2009 American Society of Hematology (ASH) annual meeting introduced novel strategies for the treatment of acute leukemia. Targeted inhibitors for both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) represent the future of these malignancies. Inclusion of targeted treatment to combination chemotherapy may translate into improved cure rates. The most clinically relevant abstracts, all of which are published in the November 2009, 114 issue of Blood, are summarized below and are identified here by their abstract numbers.

AB - The 2009 American Society of Hematology (ASH) annual meeting introduced novel strategies for the treatment of acute leukemia. Targeted inhibitors for both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) represent the future of these malignancies. Inclusion of targeted treatment to combination chemotherapy may translate into improved cure rates. The most clinically relevant abstracts, all of which are published in the November 2009, 114 issue of Blood, are summarized below and are identified here by their abstract numbers.

UR - http://www.scopus.com/inward/record.url?scp=77950448077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950448077&partnerID=8YFLogxK

U2 - 10.1002/ajh.21644

DO - 10.1002/ajh.21644

M3 - Article

AN - SCOPUS:77950448077

VL - 85

SP - 277

EP - 280

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 4

ER -